"The MitraClip(R) therapy has not only played a key role for patients considered too high-risk for surgery, but has also been shown to be effective in selected surgical candidates," added Francesco Maisano, M.D., cardiovascular surgeon at Hospital San Rafaelle, Milan, Italy. "As a cardiac surgeon, I believe that this technology has expanded the options available to physicians to the benefit of the patient suffering from MR."
As of today, patients have been treated with the MitraClip(R) system at fourteen institutions throughout Europe including the University Heart Center, Hamburg, Germany; Cardiovascular Center Frankfurt, Frankfurt, Germany; University Hospital Aachen, Aachen, Germany; University Hospital Essen, Essen, Germany; University Medicine Gottingen, Gottingen, Germany; Bernau Hospital and Heart Center, Brandenburg, Germany; Ferrarotto Hospital, Univeristy of Catania, Sicily, Italy ; Hospital San Rafaelle, Milan, Italy; St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands; Cardiocentro Ticino, Lugano, Switzerland; University Hospital, Zurich, Switzerland; Castle Hill Hospital, Hull, UK; Imperial College Hospital, London, UK; and the Academic Medical Center, Amsterdam, Netherlands.
"The successful treatment of the 100th patient in Europe with the MitraClip(R) system is an important milestone for Evalve," said Ferolyn Powell, president and chief executive officer of Evalve. "We have been pleased with expansion in the number of customers, the acceleration of the implant rate and the very positive response from physicians with regards to their ability to quickly learn and successfully perform the procedure. This, combined with their strong belief in the value of the
|SOURCE Evalve, Inc.|
Copyright©2009 PR Newswire.
All rights reserved